CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.84B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.7: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
19.10BCNY2.84B · vs all stocks (USD)
Revenue (TTM)
1.12BCNY166.71M · vs all stocks (USD)
Profit Margin
-0.09%Beta
1.22xvs all stocks
52-Week Change
-11.68%vs all stocks
Market Capitalization
19.10BCNY2.84B · vs all stocks (USD)
Enterprise Value
12.57BCNY1.87B · vs all stocks (USD)
Forward P/E
-130.95xPrice to Sales (TTM)
11.83xPrice to Book (MRQ)
2.69xEnterprise to Revenue
11.21xGross Margin
69.59%Profit Margin
-0.09%Operating Margin
-15.19%Return on Assets (TTM)
-0.83%Return on Equity (TTM)
-0.02%Revenue (TTM)
1.12BCNY166.71M · vs all stocks (USD)
Revenue per Share (TTM)
4.33CNYUpdated Aug 21, 2026Quarterly Revenue Growth
38.70%Gross Profit (TTM)
844.83MCNY125.63M · vs all stocks (USD)
EBITDA (TTM)
217.83MCNY32.39M · vs all stocks (USD)
Net Income (TTM)
-1.01MCNY-149.62K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-315.36%Operating Cash Flow (TTM)
37.76MCNY5.62M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-351.57MCNY-52.28M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
0.00CNYFY2025 · Dec 31, 2025Revenue
1.06BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
260.13MCNYFY2025 · Dec 31, 2025Gross Profit
799.26MCNYFY2025 · Dec 31, 2025Operating Income
27.21MCNY4.05M · vs all stocks (USD)
Pre-tax Income
21.74MCNYFY2025 · Dec 31, 2025Income Tax Expense
-6.13MCNYFY2025 · Dec 31, 2025Net Income
27.87MCNYFY2025 · Dec 31, 2025EBIT
61.34MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
217.83MCNYFY2025 · Dec 31, 2025Research & Development
313.04MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
589.83MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
34.77MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
39.61MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
247.01MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
247.01MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00CNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-154.98MCNYFY2025 · Dec 31, 2025Free Cash Flow
-344.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.22BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
21.74MCNYFY2025 · Dec 31, 2025Stock-based Compensation
9.38MCNYFY2025 · Dec 31, 2025Other Non-cash Items
12.98MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-52.82MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-146.26MCNYFY2025 · Dec 31, 2025Capital Expenditures
-189.68MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-53.66MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-7.63BCNYFY2025 · Dec 31, 2025Sale of Investments
8.22BCNYFY2025 · Dec 31, 2025Other Investing Activity
12.44MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
418.46MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
795.66MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.51BCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-7.31MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-714.37MCNYFY2025 · Dec 31, 2025Shares Outstanding
247.04MSharesUpdated Aug 21, 2026Float Shares
159.89MSharesUpdated Aug 21, 2026% Held by Insiders
63.46%vs all stocks
% Held by Institutions
3.67%vs all stocks
Total Cash (MRQ)
2.41BCNY358.43M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.76CNYUpdated Aug 21, 2026Total Debt (MRQ)
1.16BCNY172.77M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2359xCurrent Ratio (MRQ)
4.11xBook Value per Share (MRQ)
19.94CNYUpdated Aug 21, 2026Total Assets
7.18BCNY1.07B · vs all stocks (USD)
Total Current Assets
3.84BCNYFY2025 · Dec 31, 2025Total Liabilities
2.22BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.34BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.14BCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.08BCNYFY2025 · Dec 31, 2025Cash
1.22BCNYFY2025 · Dec 31, 2025Cash Equivalents
414.00KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.22BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.41BCNYFY2025 · Dec 31, 2025Accounts Receivable
782.88MCNYFY2025 · Dec 31, 2025Inventory
338.31MCNYFY2025 · Dec 31, 2025Accounts Payable
50.44MCNYFY2025 · Dec 31, 2025Short-term Debt
323.95MCNYFY2025 · Dec 31, 2025Long-term Debt
964.56MCNYFY2025 · Dec 31, 2025Common Stock (Book)
247.04MCNYFY2025 · Dec 31, 2025Retained Earnings
-471.44MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.95BCNY736.65M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
46.89CNYUpdated Aug 21, 202652-Week High
90.50CNYUpdated Aug 21, 202652-Week Change
-11.68%vs all stocks
Beta
1.22xvs all stocks
50-Day MA
51.35CNYUpdated Aug 21, 2026200-Day MA
62.61CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.72MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.13MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.1100CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: -0.00
Financial Health
Altman Z-Score 5.7: safe zoneNotable
Altman Z-Score: 5.70
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.84B, above the global median of $1.15BNotable
Market cap (USD): 2,840,573,163.516Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Hypera S.A.
Tier 1ProductionApproval-Gated PipelineRule
Beam Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kangmei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Joincare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharma Research Products Co., Ltd
Tier 1ProductionApproval-Gated PipelineRule
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Supernus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk